A Phase I, Randomized, Single-Blinded, Placebo-Controlled, Single-Dose, Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of MOD-6031 in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 07 Nov 2016
At a glance
- Drugs Oxyntomodulin (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors OPKO Health
- 07 Nov 2016 According to an OPKO Health media release, safety data from this trial expected early 2017.
- 17 Aug 2016 Planned End Date changed from 1 Sep 2016 to 1 Dec 2016.
- 17 Aug 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Dec 2016.